The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease
Open accessAbstract
OBJECTIVE: To assess the utility and safety of rituximab in pediatric autoimmune and inflammatory disorders of the CNS. METHODS: Multicenter retrospective study. RESULTS: A total of 144 children and adolescents (median age 8 years, range 0.7-17; 103 female) with NMDA receptor (NMDAR) encephalitis (n = 39), opsoclonus myoclonus ataxia syndrome (n = 32), neuromyelitis optica spectrum disorders (n = 20), neuropsychiatric systemic lupus erythematosus (n = 18), and other neuroinflammatory disorders (n = 35) were studied. Rituximab was given after a median duration of disease of 0.5 years (range 0.05-9.5 years). Infusion adverse events were recorded in 18/144 (12.5%), including grade 4 (anaphylaxis) in 3. Eleven patients (7.6%) had an infectious adverse event (AE), including 2 with grade 5 (death) and 2 with grade 4 (disabling) infectious AE (median follow-up of 1.65 years [range 0.1-8.5]). No patients developed progressive multifocal leukoencephalopathy. A definite, probable, or possible benefit was reported in 125 of 144 (87%) patients. A total of 17.4% of patients had a modified Rankin Scale (mRS) score of 0-2 at rituximab initiation, compared to 73.9% at outcome. The change in mRS 0-2 was greater in patients given rituximab early in their disease course compared to those treated later. CONCLUSION: While limited by the retrospective nature of this analysis, our data support an off-label use of rituximab, although the significant risk of infectious complications suggests rituximab should be restricted to disorders with significant morbidity and mortality. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in pediatric autoimmune and inflammatory CNS disorders, rituximab improves neurologic outcomes with a 7.6% risk of adverse infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Titulaer, M. J., McCracken, L., Gabilondo, I., Armangué, T., Glaser, C., Iizuka, T., Honig, L. S., Benseler, S. M., Kawachi, I., Martinez-Hernandez, E., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70310-1 · Cited by 3,165 · cited 3×
“While therapeutic efficacy could not be formally evaluated in a retrospective analysis, we evaluated the clinical disease state at initiation and following rituximab using the modified Rankin Scale (mRS) for children.(6,13) The mRS was recorded for the “worst at any stage,” at initiation of rituximab, and at outcome.”
BackgroundMethodSelf-citationRituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Tolerability and safety of rituximab (MabThera®)
Kimby, E. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.05.007 · Cited by 470
Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients
(2008) · Archives of Neurology · doi:10.1001/archneur.65.11.noc80069 · Cited by 459
Cited by
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
Ramanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316880 · Cited by 572
Self-citationNeuropsychiatric lupus: new mechanistic insights and future treatment directions
Schwartz, N., Stock, A. D., & Putterman, C. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0156-8 · Cited by 429
Hacohen, Y., Wong, Y. Y., Lechner, C., Jurynczyk, M., Wright, S., Konuskan, B., Kalser, J., Poulat, A. L., Maurey, H., Ganelin-Cohen, E., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4601 · Cited by 423
Self-citationDamato, V., Evoli, A., & Iorio, R. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1637 · Cited by 290
Metadata
- Authors
- Dale, R. C., Brilot, F., Duffy, L. V., Twilt, M., Waldman, A. T., Narula, S., Muscal, E., Deiva, K., Andersen, E., Eyre, M. R., Eleftheriou, D., Brogan, P. A., Kneen, R., Alper, G., Anlar, B., Wassmer, E., Heineman, K., Hemingway, C., Riney, C. J., Kornberg, A., Tardieu, M., Stocco, A., Banwell, B., Gorman, M. P., Benseler, S. M., & Lim, M.
- Venue
- Neurology
- Published
- 2014-07-08
- Volume
- 83
- Issue
- 2
- Pages
- 142-150
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1968634262
- Cited by
- 344
- References
- 19
- FWCI
- 19.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000000570
- The paper
- Dale, R. C., Brilot, F., Duffy, L. V., Twilt, M., Waldman, A. T., Narula, S., Muscal, E., Deiva, K., Andersen, E., Eyre, M. R., Eleftheriou, D., Brogan, P. A., Kneen, R., Alper, G., Anlar, B., Wassmer, E., Heineman, K., Hemingway, C., Riney, C. J., . . . Lim, M. (2014). Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. https://doi.org/10.1212/wnl.0000000000000570
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.